Category: 53788-12-8

On April 30, 1998, Jorand-Lebrun, Catherine; Valognes, Delphine; Halazy, Serge published an article.COA of Formula: C7H13ClN2O The title of the article was Use of triphosgene for direct preparation of carbamoyl chlorides from tertiary benzylamines. And the article contained the following:

Treatment of tribenzylamine with triphosgene in CH2Cl2 gave dibenzylcarbamoyl chloride in 71% yield. Several other amines, e.g., I (X = CO, MeN), underwent similar reactions. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).COA of Formula: C7H13ClN2O

The Article related to triphosgene reaction tertiary amine, carbamoyl chloride preparation, General Organic Chemistry: Synthetic Methods and other aspects.COA of Formula: C7H13ClN2O

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On April 30, 1998, Jorand-Lebrun, Catherine; Valognes, Delphine; Halazy, Serge published an article.COA of Formula: C7H13ClN2O The title of the article was Use of triphosgene for direct preparation of carbamoyl chlorides from tertiary benzylamines. And the article contained the following:

Treatment of tribenzylamine with triphosgene in CH2Cl2 gave dibenzylcarbamoyl chloride in 71% yield. Several other amines, e.g., I (X = CO, MeN), underwent similar reactions. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).COA of Formula: C7H13ClN2O

The Article related to triphosgene reaction tertiary amine, carbamoyl chloride preparation, General Organic Chemistry: Synthetic Methods and other aspects.COA of Formula: C7H13ClN2O

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 1, 2017, Shan, Wei-Guang; Wang, Han-Guang; Chen, Yan; Wu, Rui; Wen, Yan-Tao; Zhang, Li-Wen; Ying, You-Min; Wang, Jian-Wei; Zhan, Zha-Jun published an article.Recommanded Product: 4-Ethyl-piperazine-1-carbonyl chloride The title of the article was Synthesis of 3- and 29-substituted celastrol derivatives and structure-activity relationship studies of their cytotoxic activities. And the article contained the following:

A series of 3-carbamate and 29-ester celastrol derivatives I (R1 = H, R2 = H, Me, Et, CHMe2, CH2CH:CH2, CH2Ph, 3-ClC6H4CH2, etc.; R1 = CONMePh, piperidinocarbonyl, morpholinocarbonyl, etc.) were designed and synthesized. These analogs were evaluated for their cytotoxic activities against several cancer cell lines. Cytotoxicity data revealed that the properties of substituents and substitution position had important influence on cytotoxic activity. Modification of C-3 hydroxyl with size-limited groups did not reduce the activity obviously. The introduction of polarity group like piperazine could improve the solubility Compound I (R1 = 4-piperazinocarbonyl, R2 = CH2Ph) (II) was chosen to further evaluate anti-tumor efficacy in vivo. It showed higher inhibition rate and better safety than celastrol during in vivo experiment by intragastric administration. The preliminary antitumor studies of compound II in vivo showed that it might be promising for the development of new antitumor agents. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Recommanded Product: 4-Ethyl-piperazine-1-carbonyl chloride

The Article related to celastrol derivative preparation antitumor structure activity, c-3 hydroxyl derivatives, celastrol, cytotoxicity, in vivo activity, intragastric administration, Terpenes and Terpenoids: Triterpenes (C30), Including Limonoids and other aspects.Recommanded Product: 4-Ethyl-piperazine-1-carbonyl chloride

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 21, 1990, Kishimoto, Shoji; Fujita, Takeshi published a patent.Quality Control of 4-Ethyl-piperazine-1-carbonyl chloride The title of the patent was Preparation of O-acylfumagillol derivatives as angiogenesis inhibitors. And the patent contained the following:

The title compounds [I; R1 = CH:CMe2, (un)substituted CH2CHMe2; R2 = substituted alkanoyl, aroyl, (un)substituted heterocyclylcarbonyl, CONH2, alkyl, etc.] were prepared, e.g., by acylation of I (R2 = H). Thus, fumagillol was stirred 20 h with diglycolic anhydride in pyridine to give I (R1 = COCH2OCH2CO2H, R2 = CH:CMe2) which reduced bovine fibroblast growth factor-induced angiogenesis in cornea of 8 of 8 rats evaluated after 7 days. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Quality Control of 4-Ethyl-piperazine-1-carbonyl chloride

The Article related to fumagillol substituted preparation angiogenesis inhibitor, Terpenes and Terpenoids: Sesquiterpenes (C15), Including Ionones and other aspects.Quality Control of 4-Ethyl-piperazine-1-carbonyl chloride

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 7, 1990, Kishimoto, Shoji; Fujita, Takeshi; Kanamaru, Tsuneo; Folkman, Moses Judah; Ingber, Donald published a patent.COA of Formula: C7H13ClN2O The title of the patent was Preparation of O-acylfumagillols and analogs as angiogenesis inhibitors. And the patent contained the following:

The title compounds [I; R1 = (un)substituted CH:CMe2, CH2CHMe2; R2 = substituted alkanoyl, aroyl, (un)substituted heteroarylcarbonyl, CONH2, alkyl, PhSO2, alkylsulfonyl, H2NSO2, alkoxycarbonyl, PhO2C] were prepared Thus, fumagillol was stirred 2 h at 0° with ClCH2CONCO in CH2Cl2 containing dimethylaminopyridine to give I (R1 = CH:CMe2, R2 = CONHCOCH2Cl) which suppressed B16 mouse melanoma tumor growth to 20% that of controls after 3 wk in mice receiving 30 mg/kg s.c. every other day. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).COA of Formula: C7H13ClN2O

The Article related to acylfumagillol preparation angiogenesis inhibitor, fumagillol acyl preparation angiogenesis inhibitor, Terpenes and Terpenoids: Sesquiterpenes (C15), Including Ionones and other aspects.COA of Formula: C7H13ClN2O

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 18, 2005, Link, John O.; Graupe, Michael published a patent.Related Products of 53788-12-8 The title of the patent was Preparation of silyl-containing carboxamides as cysteine protease inhibitors. And the patent contained the following:

The present invention is directed to silyl-containing carboxamides (R3-Q-N(R2)-C(R1)(R1a)-C(O)-N(H)-E (I); variables defined below; e.g. morpholine-4-carboxylic acid [(1R)-1-[(4-cyano-1-ethylpiperidin-4-yl)carbamoyl]-2-(trimethylsilanyl)ethyl]amide (shown as II)) that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them. The present invention is also directed to the use of these inhibitors in combination with a therapy that causes a deleterious immune response in patients receiving the therapy. Although the methods of preparation are not claimed, 11 example preparations of I are included. For example, II was prepared in 2 steps starting with amide formation between (R)-2-amino-3-(trimethylsilanyl)propionic acid and morpholinocarbonyl chloride using MSTFA to give 2-(R)-[[(morpholin-4-yl)carbonyl]amino]-3-(trimethylsilanyl)propionic acid which underwent amide formation with 4-amino-4-cyano-1-ethylpiperidine hydrochloride in the presence of HATU and iPr2EtN in DMF. For I: Q is -CO-, -SO2-, -OCO-, -NR4CO-, -NR4SO2-, or -CHR- where R is haloalkyl and R4 is H, alkyl, hydroxyalkyl, alkoxyalkyl, or aralkyl; E is -C(R5)(R6)X1 (X1 is -C(R7)(R8)R10, -CH:CHS(O)2R10, -C(R7)(R8)C(R7)(R8)OR10, -C(R7)(R8)CH2OR10, -C(R7)(R8)CH2N(R11)SO2R10, -C(R7)(R8)C(O)N(R11)(CH2)2OR11, -C(R7)(R8)C(O)NR10R11 or -C(R7)(R8)C(O)N(R11)(CH2)2NR10R11) or -C(R5a)(R6a)CN. R1 is H or alkyl; R1a is 1,1-dialkylsilinan-4-ylalkylene or -(alkylene)-SiR32R33R34 where R32 is alkyl, R33 is alkyl, and R34 is alkyl, alkenyl, cycloalkylalkyl, aryl, aralkyl, heteroaralkyl, or heterocycloalkylalkyl or R33 and R34 together with Si form a heterocycloalkylene ring containing the Si atom and 3 to 7 C ring atoms wherein one or two C ring atoms are optionally independently replaced with -NH-, -O-, -S-, -SO-, -SO2-, -CO-, -CONH-, or -SO2NH-. R2 is H or alkyl; R3 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkylalkyl, or -alkylene-X6-R35 [wherein X6 is -NR36-, -O-, -S(O)n4-, -CO-, -COO-, -OCO-, -NR36CO-, -CONR36-, -NR36SO2-, -SO2NR36-, -NR36COO-, -OCONR36-, NR36CONR37- or NR36SO2NR37- (each R36 and R37 = H, alkyl, or acyl and n4 = 0-2) and R35 is H, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl]; addnl. details are given in the claims. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Related Products of 53788-12-8

The Article related to silyl carboxamide preparation cysteine protease inhibitor, cathepsin b k l f s inhibitor silyl carboxamide, Organometallic and Organometalloidal Compounds: Silicon Compounds and other aspects.Related Products of 53788-12-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 1, 2017, Shan, Wei-Guang; Wang, Han-Guang; Chen, Yan; Wu, Rui; Wen, Yan-Tao; Zhang, Li-Wen; Ying, You-Min; Wang, Jian-Wei; Zhan, Zha-Jun published an article.Recommanded Product: 4-Ethyl-piperazine-1-carbonyl chloride The title of the article was Synthesis of 3- and 29-substituted celastrol derivatives and structure-activity relationship studies of their cytotoxic activities. And the article contained the following:

A series of 3-carbamate and 29-ester celastrol derivatives I (R1 = H, R2 = H, Me, Et, CHMe2, CH2CH:CH2, CH2Ph, 3-ClC6H4CH2, etc.; R1 = CONMePh, piperidinocarbonyl, morpholinocarbonyl, etc.) were designed and synthesized. These analogs were evaluated for their cytotoxic activities against several cancer cell lines. Cytotoxicity data revealed that the properties of substituents and substitution position had important influence on cytotoxic activity. Modification of C-3 hydroxyl with size-limited groups did not reduce the activity obviously. The introduction of polarity group like piperazine could improve the solubility Compound I (R1 = 4-piperazinocarbonyl, R2 = CH2Ph) (II) was chosen to further evaluate anti-tumor efficacy in vivo. It showed higher inhibition rate and better safety than celastrol during in vivo experiment by intragastric administration. The preliminary antitumor studies of compound II in vivo showed that it might be promising for the development of new antitumor agents. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Recommanded Product: 4-Ethyl-piperazine-1-carbonyl chloride

The Article related to celastrol derivative preparation antitumor structure activity, c-3 hydroxyl derivatives, celastrol, cytotoxicity, in vivo activity, intragastric administration, Terpenes and Terpenoids: Triterpenes (C30), Including Limonoids and other aspects.Recommanded Product: 4-Ethyl-piperazine-1-carbonyl chloride

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 21, 1990, Kishimoto, Shoji; Fujita, Takeshi published a patent.Quality Control of 4-Ethyl-piperazine-1-carbonyl chloride The title of the patent was Preparation of O-acylfumagillol derivatives as angiogenesis inhibitors. And the patent contained the following:

The title compounds [I; R1 = CH:CMe2, (un)substituted CH2CHMe2; R2 = substituted alkanoyl, aroyl, (un)substituted heterocyclylcarbonyl, CONH2, alkyl, etc.] were prepared, e.g., by acylation of I (R2 = H). Thus, fumagillol was stirred 20 h with diglycolic anhydride in pyridine to give I (R1 = COCH2OCH2CO2H, R2 = CH:CMe2) which reduced bovine fibroblast growth factor-induced angiogenesis in cornea of 8 of 8 rats evaluated after 7 days. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Quality Control of 4-Ethyl-piperazine-1-carbonyl chloride

The Article related to fumagillol substituted preparation angiogenesis inhibitor, Terpenes and Terpenoids: Sesquiterpenes (C15), Including Ionones and other aspects.Quality Control of 4-Ethyl-piperazine-1-carbonyl chloride

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 7, 1990, Kishimoto, Shoji; Fujita, Takeshi; Kanamaru, Tsuneo; Folkman, Moses Judah; Ingber, Donald published a patent.COA of Formula: C7H13ClN2O The title of the patent was Preparation of O-acylfumagillols and analogs as angiogenesis inhibitors. And the patent contained the following:

The title compounds [I; R1 = (un)substituted CH:CMe2, CH2CHMe2; R2 = substituted alkanoyl, aroyl, (un)substituted heteroarylcarbonyl, CONH2, alkyl, PhSO2, alkylsulfonyl, H2NSO2, alkoxycarbonyl, PhO2C] were prepared Thus, fumagillol was stirred 2 h at 0° with ClCH2CONCO in CH2Cl2 containing dimethylaminopyridine to give I (R1 = CH:CMe2, R2 = CONHCOCH2Cl) which suppressed B16 mouse melanoma tumor growth to 20% that of controls after 3 wk in mice receiving 30 mg/kg s.c. every other day. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).COA of Formula: C7H13ClN2O

The Article related to acylfumagillol preparation angiogenesis inhibitor, fumagillol acyl preparation angiogenesis inhibitor, Terpenes and Terpenoids: Sesquiterpenes (C15), Including Ionones and other aspects.COA of Formula: C7H13ClN2O

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 18, 2005, Link, John O.; Graupe, Michael published a patent.Related Products of 53788-12-8 The title of the patent was Preparation of silyl-containing carboxamides as cysteine protease inhibitors. And the patent contained the following:

The present invention is directed to silyl-containing carboxamides (R3-Q-N(R2)-C(R1)(R1a)-C(O)-N(H)-E (I); variables defined below; e.g. morpholine-4-carboxylic acid [(1R)-1-[(4-cyano-1-ethylpiperidin-4-yl)carbamoyl]-2-(trimethylsilanyl)ethyl]amide (shown as II)) that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them. The present invention is also directed to the use of these inhibitors in combination with a therapy that causes a deleterious immune response in patients receiving the therapy. Although the methods of preparation are not claimed, 11 example preparations of I are included. For example, II was prepared in 2 steps starting with amide formation between (R)-2-amino-3-(trimethylsilanyl)propionic acid and morpholinocarbonyl chloride using MSTFA to give 2-(R)-[[(morpholin-4-yl)carbonyl]amino]-3-(trimethylsilanyl)propionic acid which underwent amide formation with 4-amino-4-cyano-1-ethylpiperidine hydrochloride in the presence of HATU and iPr2EtN in DMF. For I: Q is -CO-, -SO2-, -OCO-, -NR4CO-, -NR4SO2-, or -CHR- where R is haloalkyl and R4 is H, alkyl, hydroxyalkyl, alkoxyalkyl, or aralkyl; E is -C(R5)(R6)X1 (X1 is -C(R7)(R8)R10, -CH:CHS(O)2R10, -C(R7)(R8)C(R7)(R8)OR10, -C(R7)(R8)CH2OR10, -C(R7)(R8)CH2N(R11)SO2R10, -C(R7)(R8)C(O)N(R11)(CH2)2OR11, -C(R7)(R8)C(O)NR10R11 or -C(R7)(R8)C(O)N(R11)(CH2)2NR10R11) or -C(R5a)(R6a)CN. R1 is H or alkyl; R1a is 1,1-dialkylsilinan-4-ylalkylene or -(alkylene)-SiR32R33R34 where R32 is alkyl, R33 is alkyl, and R34 is alkyl, alkenyl, cycloalkylalkyl, aryl, aralkyl, heteroaralkyl, or heterocycloalkylalkyl or R33 and R34 together with Si form a heterocycloalkylene ring containing the Si atom and 3 to 7 C ring atoms wherein one or two C ring atoms are optionally independently replaced with -NH-, -O-, -S-, -SO-, -SO2-, -CO-, -CONH-, or -SO2NH-. R2 is H or alkyl; R3 is alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkylalkyl, or -alkylene-X6-R35 [wherein X6 is -NR36-, -O-, -S(O)n4-, -CO-, -COO-, -OCO-, -NR36CO-, -CONR36-, -NR36SO2-, -SO2NR36-, -NR36COO-, -OCONR36-, NR36CONR37- or NR36SO2NR37- (each R36 and R37 = H, alkyl, or acyl and n4 = 0-2) and R35 is H, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl]; addnl. details are given in the claims. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Related Products of 53788-12-8

The Article related to silyl carboxamide preparation cysteine protease inhibitor, cathepsin b k l f s inhibitor silyl carboxamide, Organometallic and Organometalloidal Compounds: Silicon Compounds and other aspects.Related Products of 53788-12-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics